• Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation for its new product Trecondi® (treosulfan) on 20 June 2019. medac‘s haematology portfolio is strengthened once again with this innovative therapeutic agent.

    Trecondi® is the first and only product containing treosulfan to have received marketing authorisation in Germany in haematology and therefore offers a new perspective compared with previous therapies.

    medac will begin the official sale of Trecondi® in Germany in August.

    Nach oben